With more intensive scrutiny of cancer genomes, RET mutations continue to be recognized, but many tumor types are now also being found to respond to GFLs released in the microenvironment by the tumor itself or neighboring cells, expanding the range of pathologies that may benefit from targeting this pathway. The gene discussed is RET; the disease is cancer.